Literature DB >> 32647027

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.

Nicola Potere1,2, Marcello Di Nisio3,4, Donatella Cibelli5, Rosa Scurti6, Antonella Frattari7, Ettore Porreca1, Antonio Abbate2, Giustino Parruti8.   

Abstract

Entities:  

Keywords:  biological therapy; cytokines; immune system diseases; inflammation

Year:  2020        PMID： 32647027     DOI： 10.1136/annrheumdis-2020-218243

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  19 in total

Review 1.  Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Qi Han; Mingyue Guo; Yue Zheng; Ying Zhang; Yanshan De; Changchang Xu; Lin Zhang; Ruru Sun; Ying Lv; Yan Liang; Feng Xu; Jiaojiao Pang; Yuguo Chen
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

Review 2.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

3.  Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis.

Authors:  Chi-Chung Chen; Yu-Pei Yang; Hsien-Lung Tsai; Tao-Hsin Tung
Journal:  Front Med (Lausanne)       Date:  2022-03-30

Review 4.  Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles.

Authors:  Sherif M Shoieb; Mahmoud A El-Ghiaty; Ayman O S El-Kadi
Journal:  Emergent Mater       Date:  2020-11-17

5.  COVID-19: Imbalanced Immune Responses and Potential Immunotherapies.

Authors:  Bing Xie; Jiancheng Zhang; Yuwen Li; Shiying Yuan; You Shang
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

6.  Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis.

Authors:  Weijun Jiang; Weiwei Li; Qiuyue Wu; Ying Han; Jing Zhang; Tao Luo; Yanju Guo; Yang Yang; Peiran Zhu; Xinyi Xia
Journal:  Infect Dis Ther       Date:  2021-07-09

7.  The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.

Authors:  Avi Gurion Kaye; Robert Siegel
Journal:  PeerJ       Date:  2020-11-02       Impact factor: 2.984

Review 8.  Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019.

Authors:  Leo F Buckley; George F Wohlford; Clara Ting; Abdullah Alahmed; Benjamin W Van Tassell; Antonio Abbate; John W Devlin; Peter Libby
Journal:  Crit Care Explor       Date:  2020-08-10

9.  The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients.

Authors:  Vincenzo Bruzzese; Antonio Ivan Lazzarino
Journal:  Med Hypotheses       Date:  2020-09-18       Impact factor: 1.538

10.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

Authors:  John H Stone; Matthew J Frigault; Naomi J Serling-Boyd; Ana D Fernandes; Liam Harvey; Andrea S Foulkes; Nora K Horick; Brian C Healy; Ruta Shah; Ana Maria Bensaci; Ann E Woolley; Sarah Nikiforow; Nina Lin; Manish Sagar; Harry Schrager; David S Huckins; Matthew Axelrod; Michael D Pincus; Jorge Fleisher; Chana A Sacks; Michael Dougan; Crystal M North; Yuan-Di Halvorsen; Tara K Thurber; Zeina Dagher; Allison Scherer; Rachel S Wallwork; Arthur Y Kim; Sara Schoenfeld; Pritha Sen; Tomas G Neilan; Cory A Perugino; Sebastian H Unizony; Deborah S Collier; Mark A Matza; Janeth M Yinh; Kathryn A Bowman; Eric Meyerowitz; Amna Zafar; Zsofia D Drobni; Marcy B Bolster; Minna Kohler; Kristin M D'Silva; Jonathan Dau; Megan M Lockwood; Caroline Cubbison; Brittany N Weber; Michael K Mansour
Journal:  N Engl J Med       Date:  2020-10-21       Impact factor: 176.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.